CSIMarket


Regenicin Inc   (RGIN)
Other Ticker:  
 


 

Regenicin Inc

RGIN's Financial Statements and Analysis



Regenicin Inc reported break-even for the second quarter of 2023 compare to earnings per share of $0.00 recorded in the same quarter a year ago an improvement compare to $0.00 realized in previous quarter.


second quarter of 2023
Earnings Per Share Revenues
$ 0 $  0 Mill
Unch.     Unch.    



Regenicin Inc 's Revenue fell by 0 % in second quarter of 2023 (Mar 31 2023) year on year, to $0 million and declined by sequentially.


Regenicin Inc is

More on RGIN's Income Statement



Regenicin Inc in the second quarter of 2023 recorded net loss of $-0.354 million, an increase from net loss of $-0.184 million in II. Quarter a year ago.

Sequentially net loss advanced

More on RGIN's Growth

Regenicin Inc Inventories
In Mar 31 2023 company's net cash and cash equivalents decreased by $-1 million


Regenicin Inc





Company repurchased 0.00 million shares or 0.00 % in Mar 31 2023.


More on RGIN's Dividends

 Market Capitalization (Millions) 0
 Shares Outstanding (Millions) 153
 Total Debt (Millions $) 0
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 11
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Regenicin Inc





Company repurchased 0.00 million shares or 0.00 % in Mar 31 2023.


More on RGIN's Balance Sheets

 Market Capitalization (Millions) 0
 Shares Outstanding (Millions) 153
 Total Debt (Millions $) 0
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 11
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Regenicin Inc Earnings

Regenicin Inc Releases Q2 2023 Financial Results with Significant Operating Shortfall of $-0.327836 Million

Regenicin Inc: A Closer Look at Its Q2 2023 Financial Results
The Medical Equipment and Supplies sector has been a major player in the healthcare industry, with bellwether companies leading the way in terms of financial performance. However, as the sector grows, smaller companies are also emerging and attempting to make a name for themselves.
Regenicin Inc is one such company that has caught the attention of investors. Recently, the company released its Q2 2023 financial results, indicating a significant operating shortfall of $-0.327836 million. Although the designated revenue has not been revealed, it can be compared to the company's Q2 2022 performance, which reported a similar operating shortfall...


Date modified: 2023-05-16T20:01:37+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com